U.S. FDA Grants Reunion Neuroscience's Luvesilocin (RE104) Breakthrough Therapy Designation Status

-- Breakthrough Therapy Designation Based on Positive RECONNECT Phase 2 Clinical Data ---- Aligned with U.S. Food and Drug Administration on Registrational Path for Luvesilocin in Postpartum Depression (PPD); On Track to Initiate Phase 3 Trial in 2026 --  MORRISTOWN, N.J., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Reunion Neuroscience, Inc., a clinical-stage biopharmaceutical company committed to revolutionizing the treatment of underserved mental health disorders through the advancement of next-generation psychede ...